Literature DB >> 21110782

Iron homeostasis and methionine-centred redox cycle in nasal polyposis.

Vladimir Vinokur1, Eduard Berenshtein, Mottie Mordechai Chevion, Ron Eliashar.   

Abstract

Nasal polyposis is a multifactorial disease with a strong inflammatory component. Its pathogenesis is often associated with ROS production catalysed by redox-active iron. This study aimed to characterize the roles of iron homeostasis and redox status in the pathogenesis of polyposis. Nasal polyps (NP) from asthmatics and non-asthmatics and turbinates from controls and NP-patients were analysed for ferritin, ferritin-bound iron (FBI) and levels of methionine-centred redox cycle proteins. The ferritin content in both NPs was significantly higher than in adjacent turbinates. No differences in FBI were observed between both NP groups and both turbinates groups, while in NPs it was significantly higher. In NP-turbinates the highest levels of redox proteins were observed. In conclusion, re-distribution of iron occurs upon the development of NP. While FBI is elevated in NPs, the adjacent turbinate remain iron-poor and low-inflammatory, suggesting the formation of virtual boundary between these tissues.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21110782     DOI: 10.3109/10715762.2010.535531

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  2 in total

1.  DCBLD2 gene variations correlate with nasal polyposis in Korean asthma patients.

Authors:  Charisse Flerida A Pasaje; Joon Seol Bae; Byung-Lae Park; Hyun Sub Cheong; Jeong-Hyun Kim; An-Soo Jang; Soo-Taek Uh; Choon-Sik Park; Hyoung Doo Shin
Journal:  Lung       Date:  2012-01-21       Impact factor: 2.584

2.  Zn/Ga-DFO iron-chelating complex attenuates the inflammatory process in a mouse model of asthma.

Authors:  Haim Bibi; Vladimir Vinokur; Dan Waisman; Yigal Elenberg; Amir Landesberg; Anna Faingersh; Moran Yadid; Vera Brod; Jimy Pesin; Eduard Berenshtein; Ron Eliashar; Mordechai Chevion
Journal:  Redox Biol       Date:  2014-06-18       Impact factor: 11.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.